Mark your calendars for October 1-2, 2026, for the 6th annual Bringing Chemistry to Medicine Symposium. This hybrid event features talks by leading experts from around the globe working at the interface of chemical biology and biomedical sciences. Speakers represent expertise across various research areas, including therapeutic regulation of transcription and chromatin, AI, data science, and chemical biology.
The symposium is hosted by the St. Jude Chemical Biology and Therapeutics and the St. Jude Comprehensive Cancer Center. The event is designed to advance collaboration and engagement in the emerging field of transcription-targeted therapeutics.
This symposium will be hosted in a hybrid format, giving you the option to attend in-person and to enjoy the enhanced networking and experience the beautiful St. Jude campus in Memphis, TN. As always, we also welcome virtual attendees to join us from around the world. To encourage broad participation from researchers around the world registration is free.
Speakers for the 2026 symposium will be announced soon. Sign up for updates when registration is open.
Sign up to receive announcements and updates for Bringing Chemistry to Medicine
Scenes from the 2025 symposium
Watch our Archived Lectures
Each year since 2020, St. Jude has hosted exciting two-day events focused on Transcription Therapy and Chemical Biology and Therapeutics.
Transcription Therapy at St. Jude
Over decades of research, scientists in the St. Jude Comprehensive Cancer Center and others have discovered that several pediatric cancers emerge due to disruption in chromatin and epigenetic states and dysfunctional transcriptional regulation. While gene regulation in general has long been considered “undruggable,” scientists in the St. Jude Department of Chemical Biology & Therapeutics (CBT) have created synthetic gene regulators and are devising new chemical approaches to inhibit or degrade malfunctioning components of chromatin and gene regulatory machineries. This work builds on the history of St. Jude as a pioneer in the therapeutic use of small molecules targeting gene regulation, most notably the application of glucocorticoid receptor agonists into chemotherapy regimens for pediatric patients with acute lymphoblastic lymphoma (ALL). The drugging of this transcription factor helped to dramatically increase overall survival rates for newly diagnosed ALL to 94% at St. Jude.
Learn more about transcription therapy at St. Jude Learn more